Base business breakout buried under ibuprofen's ₹700 Crore anchor
The base business finally broke through to a new level—₹307 Crore quarterly revenue (+24% YoY) with ₹72 Crore EBITDA—but the consolidated result is muddied by ₹700 Crore deployed in ibuprofen earning indefinite losses. The market's 20% drawdown from all-time high is the market's own verdict on the print.
₹381.6 Cr
+19.6% YoY
₹307 Cr
+24% YoY (80% of consolidated)
-12%
₹10–15 Cr quarterly loss normalized
₹30 Cr
West Asia solvent crisis; ₹17–18 Cr with pricing power
On the surface this looks like a clean turnaround: PAT up 55% YoY, EBITDA a 18-quarter high, debt cut ₹135 Crore in a single quarter. But strip out the ibuprofen unit and the base business story is even more impressive—24% revenue growth, crossing a new ₹300+ Crore quarterly plateau that was ₹245–248 Crore just a year ago. The problem is that ibuprofen, having already consumed ₹700 Crore in deployed capital, continues to drag consolidated margins with indefinite -12% EBITDA losses (₹10–15 Crore quarterly). Management deferred the strategic review for a decision to September again, offering no new clarity on exit value or timeline.
What actually happened: base breaks through, ibuprofen doesn't improve
The consolidated ₹381.6 Crore result masks a bifurcated performance. Base business—the non-ibuprofen API portfolio (50–60 products, 15–16 drive 75% of revenue)—delivered ₹307 Crore, up 24% YoY, with EBITDA of ₹72 Crore (23.5% margin on the base, target 25% ±1%). This is real momentum: capacity utilization 70% across three sites (Cuddalore, Bangalore, Ambernath) leaves room to scale. Management guided 10% growth from the base going forward; they're already at 24%, suggesting either sandbagged guidance or genuine confidence in sustaining high single-digits at minimum. Ibuprofen, meanwhile, remains a capital sink. Revenue ~₹77 Crore, EBITDA margin -12%, normalized to ₹10–15 Crore quarterly losses indefinitely. No improvement pathway is articulated. This isn't a turnaround unit; it's a normalized loss center, and the ₹700 Crore of capital is unlikely to be recovered in full. The Vizag facility, where ibuprofen is manufactured, remains mothballed pending the H1 FY27 strategic decision.
Consolidated margin: PAT of ₹16.3 Crore is 4.2% of revenue, well below the base business's 20%+ share. This gap—ibuprofen diluting the consolidated story by 2–3 percentage points of PAT margin—is the structural problem no efficiency gain can solve unless the capital is reallocated or ibuprofen exits.
The cost pass-through question
Base business gross margin contracted to 51.3% in Q1 from 54%+ in prior quarters. Of the ₹30 Crore in revenue tied to cost pass-through (8% of consolidated revenue), about ₹17–18 Crore comes from West Asia solvent supply crisis—raw materials are up 30%, lines shut intermittently, and management is passing costs to customers. This is not purely organic growth; organic volume growth is closer to 18–19% YoY once pricing is stripped out. The question: how much of the ₹30 Crore price cushion persists as West Asia normalizes? Management guided that 52–55% gross margin is the comfortable range for base business, implying a reversion to 54–55% margin once cost inflation moderates. If the ₹17–18 Crore solvent pass-through is temporary and reverses in H2 FY27, base business margin could expand back to historical 25% EBITDA (vs. 23.5% delivered). But if it lingers or if raw material costs remain elevated, the margin ceiling comes down. This is the key watch for Q2.
Overall revenue ₹384 Cr, up 20% YoY
Delivered ₹381.6 Cr, +19.6% YoY
Slightly overstated by 0.4 percentage points
Base business up 24% YoY with sustained gross margins
Base ₹307 Cr (+24% YoY), gross margin 51.3% vs 54%+ prior; adjusted 54.5% ex cost pass-through
Supported (margin compression temporary, tied to cost headwinds)
Highest PAT and EBITDA in 18 quarters
PAT ₹16.3 Cr, EBITDA ~₹62 Cr confirmed
Supported
Can sustain/grow at new ₹300+ Cr base business revenue level
Revenue -1.5% QoQ consolidated; base likely -2 to -3% QoQ. Q1 seasonally weak in APIs
Partial—flat QoQ despite 24% YoY suggests volume momentum soft once pricing factored in
Ibuprofen margins likely to sustain or improve from -12%
Management expects -12% to continue, ₹10–15 Cr quarterly loss normalized going forward
Contradicted—no improvement trajectory; purely a capital sink
What changed on this call
Base business crossed ₹300 Cr quarterly plateau from ₹245–248 Cr prior year
Debt reduction pace: ₹135 Cr cut (22% in Q1) via ₹100 Cr rights issue + ₹35 Cr ops cash; targeting ₹440 Cr by end-FY27 (1.7x EBITDA)
Ibuprofen decision deferred again: H1 FY27 (Sep 2026) expected; no new milestones shared since Q4 guidance
Capacity utilization disclosed: base business 70% across three sites; Vizag mothballed pending CRAMS decision
Debottlenecking capex plan firmed: ₹40 Cr FY27 targeting 20–30% capacity gains on high-margin lines (2–3 quarter payback); ₹40–50 Cr annually FY28–29
The bull-bear ledger
Base business genuine 24% momentum, now at a sustainably higher ₹300+ Cr level; management confident of at least 10% growth going forward
Debt deleveraging impressive: ₹135 Cr (22%) reduction in Q1; ₹100 Cr from rights issuance, ₹35 Cr from ops cash; on track for 1.7x target by FY27 end and net debt free by FY29
Margin profile intact for base: 51.3% gross margin adjusted to 54.5% ex cost pass-through; 25% EBITDA margin reaffirmed as target (23.5% delivered, expected to revert post-cost normalization)
Capex discipline: debottlenecking, not greenfield; ₹40 Cr FY27 targeting 20–30% capacity gains on high-margin lines with 2–3 quarter payback
Ibuprofen is a ₹700 Cr capital trap: -12% EBITDA margin expected to persist at ₹10–15 Cr quarterly loss; full capital recovery unlikely; decision deferred again to Sep
Near-term margin compression from West Asia: ₹30 Cr cost pass-through (8% of revenue), of which only ₹17–18 Cr has pricing power; remainder at risk of reversal as crisis moderates
QoQ revenue flat (-1.5% consolidated, likely -2 to -3% base) despite 24% YoY growth suggests volume momentum soft once pricing factored out; Q1 is seasonally weak for APIs
Still leveraged at 1.9x EBITDA (₹479 Cr net debt); deleveraging path contingent on base growth sustaining and ibuprofen not requiring additional capex
Customer pricing resistance risk: some customers unwilling to accept cost pass-through; West Asia headwinds could tighten working capital further
Ranked risks to a holder
Ibuprofen capital recovery failure
High₹700 Cr deployed earning -12% EBITDA margin indefinitely. Exit expected by Sep 2026. If management recovers less than 50% of capital or divestment forces a write-down, consolidated balance sheet impaired. Full recovery is noted as unlikely.
West Asia solvent crisis supply disruption
HighLines shut intermittently; raw materials up 30%. ₹30 Cr revenue benefit is 8% of Q1 consolidated. If solvent supply remains constrained beyond H2 FY27, lines run at lower utilization and base volume growth decelerates. Some customers resist price increases; revenue mix could compress.
Base business growth deceleration
MediumDelivered 24% YoY but flat QoQ, and organic growth (ex pricing) is 18–19% YoY. If West Asia cost reversal and volume normalization coincide, base growth could fall below 10% guided level. Capacity utilization at 70% leaves room, but customer concentration (15–16 of 50–60 products drive 75% revenue) is a risk if major customer softens demand.
Margin volatility on raw material cost swings
MediumBase business gross margin swung 50–55% range historically; Q1 51.3%, management expects reversion to 55% end of range once costs normalize. If raw material inflation persists or if cost pass-through stalls, margin ceiling compresses and EBITDA guidance (25% ±1% base) is at risk.
Debt refinancing risk on higher rates
MediumStill at ₹479 Cr net debt (1.9x EBITDA). If credit tightens or base growth slows, refinancing costs rise and interest burden pressures margins. Deleveraging plan assumes base growth sustains; if momentum stalls, debt reduction path delays.
How the street is positioned (and what it's saying about the story)
The stock is down 20.63% from its all-time high of ₹647 and trading at ₹513.55—well below its 20-, 50-, and 200-day simple moving averages (₹546, ₹557, ₹532 respectively). RSI at 20.2 signals oversold conditions, typically a technical setup for mean reversion. But the price action post-announcement is telling: the day-1 decline of -6.07% has only partially recovered to -3.01% by day 5, suggesting the market's skepticism on ibuprofen resolution is hardening, not softening. The stock had rallied modestly ahead of the result before falling sharply on announcement, indicating the market was not convinced the base business beat would overcome the ibuprofen overhang.
Institutional flows are neutral-to-negative. FII ownership has declined steadily from 14.63% (Q1 FY26) to 11.33% (Q1 FY27)—a 330 basis point drift out over 18 months. DII, meanwhile, has nudged up slightly (2.59% → 3.78%) but from a thin base. Promoter holding stable at 42%. The bulk deal on July 10 (TPG Growth IV selling 3 lakh shares @ ₹573.20) deserves attention: TPG exited at a price 11.6% above the current level, suggesting exit into strength. The stock has fallen ₹59.65 since that bulk sale, validating whatever forward view TPG held at the time.
The technical oversold condition could trigger a near-term bounce, but the fundamental overhang (ibuprofen's ₹700 Cr deployment on -12% margins indefinitely) caps sustained upside. The market is pricing in that ibuprofen value recovery is minimal and weighing the base business accordingly. Re-rating depends entirely on Sep 2026 decision clarity—until that hinge pin moves, the stock will remain a debate between base business bulls and ibuprofen bears.
The debate
What to watch next (the 2–3 things that resolve the debate)
1 · Sep 2026 (Q2 FY27): Ibuprofen strategic decision
Management committed to finalize H1 FY27 decision on ibuprofen exit, restructure, or continuation. This is the third time they've promised Sep clarity (Q4 guided it, Q1 reaffirmed it with no new progress). If they defer again, credibility collapses. If they announce divestment, the market will ask: at what price? Is the capital loss 20%, 50%, or higher? Watch the write-down magnitude and the proceeds allocation (debt reduction vs. base capex).
2 · Q2 organic base business growth delivery
Base business delivered 24% YoY in Q1 but flat QoQ. Q2 will show whether the ₹307 Cr quarterly level is a plateau or a trough. Organic growth (ex cost pass-through) needs to stay at 15%+ YoY for the base story to hold. If Q2 shows deceleration below 15% YoY (before any West Asia normalization), volume momentum concerns are validated.
3 · H2 FY27: Gross margin recovery to 25% EBITDA range for base
Q1 delivered 23.5% (₹72 Cr / ₹307 Cr), compressed by ₹17–18 Cr West Asia cost pass-through. As solvent costs normalize (expected H2 FY27 at earliest), base business margin should revert toward 25% ±1% target. If H2 margins stay depressed below 24%, either cost pass-through is losing traction or product mix is shifting to lower-margin lines—either is a red flag.
The single number to track
From here: base business EBITDA per quarter. Q1 was ₹72 Crore. Management targets ₹72+ Cr (25% margin on ₹300+ Cr revenue) sustainably. That number will answer whether the turnaround is real or a seasonally boosted one-timer. If base EBITDA stays at ₹70+ Cr sequentially, consolidated debt reduction and margin expansion follow. If it falls below ₹65 Cr, the bull thesis is in trouble.
Solara has a real base business turnaround happening—₹307 Crore of revenue at 25% margins in a business with 70% capacity utilization leaves room to grow sustainably. The trouble is that ibuprofen, a ₹700 Crore capital deployment earning -12% EBITDA margins indefinitely, is anchoring consolidated returns to a ceiling until resolved. The market's 20% drawdown from all-time high and the post-announcement fade from -6% to -3% both track this single concern: ibuprofen decision clarity by September. Until that hinge pin moves, the base business turnaround will struggle to re-rate, and the stock will remain a debate, not a conviction.
Solara Q1 PAT up 55% YoY to ₹16.3 Cr on 20% revenue growth; net margin widens to 4.3%
PAT +55.04% YoY · revenue +19.57% · margins expanding · beat vs street
₹381.6 Cr
+19.57% YoY
₹16.31 Cr
+55.04% YoY
4.24%
+1pp YoY
₹3.52
Solara Active Pharma delivered a strong Q1 FY27 on a consolidated basis, with net profit rising 55% year-on-year to ₹16.31 Cr (from ₹10.52 Cr) and 70% sequentially (from ₹9.60 Cr), on revenue of ₹381.60 Cr that grew 19.6% YoY though it eased 1.5% from Q4's ₹387.29 Cr. With brought-forward losses of ₹286 Cr shielding the P&L, the tax charge was nil, so the entire pre-tax profit dropped to the bottom line and net margin widened to 4.27% from 3.29% a year ago; EPS rose to ₹3.52 from ₹2.46. The result comfortably beat modest street expectations — previews had pencilled in revenue of roughly ₹266–300 Cr against the ₹319 Cr year-ago base.
Q1 FY-2027 vs prior quarters
The quality of the print is mixed beneath the headline: operating margin actually compressed to ~16.2% from 17.9% a year earlier, as materials consumed climbed to ~51% of sales from ~46%, signalling gross-margin give-back even as the top line grew. The PAT jump was instead powered by operating leverage on fixed costs and a lower finance bill (₹21.6 Cr vs ₹23.9 Cr). On the Q4 call management guided to sequential improvement in the base business without a formal quantitative outlook, and the QoQ profit step-up meets that framing. There were no exceptional items this quarter, so reported and adjusted YoY growth are identical at ~55%. The standalone entity earned ₹16.99 Cr on the same ₹381.60 Cr revenue, consistent with the consolidated story. Concurrent with results, the company continues to wind down its ₹449.95 Cr rights issue (₹442.73 Cr collected, final reminder-cum-forfeiture notices issued for shortfalls); the flagged items ahead are the H1 FY27 decision on the underperforming ibuprofen business and the Vizag facility roadmap management named as priorities.
The stock went into the print at ₹546.1, down 5.7% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters.
What the summary numbers don't show
Rights issue at ₹442.73 Cr collected of ₹449.95 Cr — company still carries ₹286 Cr accumulated losses, going-concern note reiterated
Management expressed confidence in sustained strong performance driven by the base business, targeting quarter-over-quarter improvement. While no specific quantitative outlook for FY27/FY28 was provided, the focus is on leveraging existing capacity and improving operational efficiencies within the base business. Strate
— This quarter: met
W1
Strategic decision on the underperforming ibuprofen business due in H1 FY27, with Vizag facility roadmap to follow (management guidance)
W2
Gross-margin trajectory: materials at ~51% of sales this quarter vs ~46% year-ago — whether base-business mix restores the Q4 FY26 eight-quarter-high margin
W3
Debt-free-by-FY29 target: ₹7.2 Cr of rights-issue calls still uncollected (₹442.73 Cr of ₹449.95 Cr received)
Digital PDF, figures clear in ₹ Cr. Tax nil both periods (brought-forward losses ₹286.21 Cr consol / ₹285.73 Cr standalone; going-concern note reiterated). No exceptional items in current quarter (Q4 FY26 had +₹0.86 Cr; FY26 had -₹5.89 Cr). Net margin expanded YoY but operating margin compressed as materials rose to ~51% of sales vs ~46%. Standalone PAT ₹16.99 Cr slightly above consolidated ₹16.31 Cr due to small subsidiary drag.
Base pivot gains traction, but ibuprofen overhang and cost headwinds cap upside
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met PAT guidance (16.3 Cr), but guided 20% revenue growth; delivered 19.6%. Ibuprofen timeline repeatedly pushed out (H1 now expected, unclear if H1 means Sep or Dec). 25% EBITDA margin for base reaffirmed from Q4, but Q1 base delivery at 23.5% under pressure. 10% base growth guidance vs 24% delivery suggests prior guidance intentionally conservative.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Base business turnaround is real (24% growth, 72 Cr EBITDA, 135 Cr debt cut in Q1), but ibuprofen remains a ₹700 Cr capital trap with -12% margin expected to persist. Near-term margins compressed by West Asia cost headwinds (₹17-18 Cr price pass-through); flat QoQ revenue suggests volume momentum soft once pricing factored in. Debt reduction impressive but at 1.9x EBITDA still leveraged. Ibuprofen decision deferred again to H1 FY27 with no new clarity.
₹381.6 Cr
Revenue · +19.6% YoY₹16.3 Cr
Reported PAT · +55% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Overall revenue INR384 Cr, up 20% YoY
OVERSTATEDDelivered 381.6 Cr, 19.6% YoY growth
Base business up 24% YoY with sustained gross margins
METBase 307 Cr (+24% YoY) but gross margin 51.3% vs prior 54%+ due to 17-18 Cr cost pass-through
Highest EBITDA and PAT in 18 quarters
METPAT 16.3 Cr confirmed, EBITDA ~62 Cr (implied margin 16.2%), need prior comparisons to verify
Can sustain/grow at new 300+ Cr base business revenue level
PartialFlat QoQ revenue (-1.5% consolidated, likely -2 to -3% for base) despite 24% YoY; Q1 seasonally weak in API
Ibuprofen margins likely to sustain or improve from -12%
MISSManagement expects -12% to continue, with ₹10-15 Cr quarterly loss normalized
Earnings quality
What changed since the last call
Base business growth acceleration
UpgradeQ1 FY27 base revenue ₹307 Cr (+24% YoY), up from prior ₹248 Cr (Q1 FY26). Crossed ₹300 Cr plateau. Prior guidance vague; now shows sustained momentum at higher level.
Debt reduction pace
UpgradeNet debt reduced ₹135 Cr in Q1 (22% decline to ₹479 Cr). ₹100 Cr from rights issue, ₹35 Cr from ops cash flow. Ahead of prior implied 1.7x target for end-FY27.
Ibuprofen decision timeline
WithdrawnQ4 guided 'H1 FY27' decision; Q1 reaffirmed same H1 timeline with no new progress. ~₹700 Cr deployed, expected to run at ₹10-15 Cr quarterly loss going forward—no upside scenario articulated.
Margin guidance clarity
Neutral25% EBITDA margin ±1% for base business restated (Q4 guidance). Q1 delivered 23.5% (72/307), compressed by cost headwinds and product mix. Guidance reaffirmed but not upgraded.
Capacity utilization update
NewBase business capacity utilization 70% across three sites (Cuddalore, Bangalore, Ambernath). Vizag remains mothballed. Implies room for ₹40 Cr debottlenecking capex to yield 20-30% capacity gains on high-margin lines.
The Q&A
Analysts pressed hard on ibuprofen capital recovery (Zakir Naseer), gross margin volatility over quarters (Akash Jain), and sustainability of 24% growth (Shashwat Singh). Management stood firm on numbers but deferred ibuprofen decision again. One dodged: CIO hire question (policy not to comment on individuals). Overall tone: respectful but skeptical on ibuprofen; base business narrative accepted.
Operational priorities next 12-18 months — Sajal Kapoor, Antifragile Thinking
AnsweredThree levers: (1) expand existing business, seed new; (2) drive operational efficiency via debottlenecking, not greenfield; (3) optimize working capital for free cash generation.
Ibuprofen strategic timeline — Sajal Kapoor, Antifragile Thinking
PartialOn track for H1 solution. Working toward optimum solution; fairly confident it will come out by H1. Address details in September.
Profitability drivers post normalization — Sajal Kapoor, Antifragile Thinking
AnsweredMost growth from business expansion and gross margin expansion via incremental volumes. Limited operating leverage; will focus on top-line growth combined with margin expansion.
Gross margin volatility — Akash Jain, Moneycurves Analytics
Answered50-55% comfortable range. Product mix, quarterly linearity, and cost pass-through all vary. Adjusted for ₹17-18 Cr cost pass-through, base business margin 54.5%, in line with prior quarters.
Volume vs value growth split — Akash Jain, Moneycurves Analytics
Answered~₹30 Cr revenue from cost pass-through. Good customer relationships; most accepting price increases after transparent communication of cost norms. Few resistant; managing dynamic.
Ibuprofen capital deployment — Anand Mundra, Soar Wealth
Answered~₹700 Cr deployed.
Ibuprofen profitability outlook — Anand Mundra, Soar Wealth
AnsweredCommodity business with solvent supply constraints. Expect to sustain at ₹10-15 Cr quarterly EBITDA loss going forward, similar to Q1 run rate.
Macro headwinds: fuel and tariffs — Parth Mehta, Antique Stock Broking
AnsweredWest Asia crisis is ongoing challenge: raw material availability and pricing both pressured. Transparent with customers on incremental costs; confident on maintaining gross margin absolute value. US tariffs: no formal policy yet; awaiting scope clarification (formulations only vs APIs).
Revenue growth flatness QoQ — Aman Chakraborty, AK Investment
AnsweredQ1 seasonally weak in API. Product basket 50 products; 15-16 drive 75% revenue. YoY growth 24% more meaningful (organic 18-19% after cost adjustment). Base business now at ₹300 Cr+ plateau vs ₹245-248 Cr prior.
Debt reduction path — Gautami Agarwal, Individual Investor
PartialInternally targeting net debt free by FY29. Will have gross debt on books but net debt zero. Slightly hesitant to give tighter timeline; no formal guidance beyond FY29.
Base business EBITDA margin sustainability — Gautami Agarwal, Individual Investor
Answered25% plus/minus 1% should be margin profile for base business EBITDA. Reaffirming prior guidance; not committing to exceed.
Ibuprofen reconsideration on price recovery — Zakir Naseer, Individual Investor
AnsweredAll decisions reconsidered if profitable. But ibuprofen is commodity; margins never match base business. Have other manufacturers; dynamics won't change. Margins fundamental constraint.
Ibuprofen capital recovery expectations — Zakir Naseer, Individual Investor
PartialRecovering entire ₹700 Cr unlikely. Finalizing next steps by Q2 results; will share clarity then on cutoff/write-down.
Working capital discipline going forward — Sajal Kapoor, Antifragile Thinking
AnsweredWorked down rigorously for turnaround. Not expecting efficiency hit from revenue growth; working on S&OP to improve inventory. Aspiration is to improve efficiency, not sacrifice it for growth.
3-year capex and capital allocation plan — Sajal Kapoor, Antifragile Thinking
AnsweredGreenfield not in plan (once bitten, twice shy). FY27 ₹55-60 Cr: ₹40 Cr debottlenecking (high-margin lines 20-30% capacity gains, 2-3 quarter payback), ₹10-15 Cr maintenance. FY28-29 similar: ₹40-50 Cr annually. Vizag remains mothballed; decision pending by Q2.
Maintenance capex efficiency gains — Sajal Kapoor, Antifragile Thinking
AnsweredNew reactors have better operational days, reduced leaks/wear-tear. Absolute output volume increases (operational days improve). Not necessarily yield improvement, but higher throughput.
Base business capacity utilization — Akash Jain, Moneycurves Analytics
AnsweredBase business three sites (Cuddalore, Bangalore, Ambernath): ~70% average capacity utilization. Vizag mothballed; plan to retrofit for CRAMS on hold pending H1 decision. CRAMS demerger status TBD.
CIO hire and innovation pipeline — Prince, Individual Investor
DodgedPolicy not to comment on individuals. Question skipped.
Ibuprofen enzymatic manufacturing update — Prince, Individual Investor
AnsweredIbuprofen not manufactured via enzymatic route. Correction made.
Base business growth drivers sustainability — Shashwat Singh, Bajaj
AnsweredGrowth from: (1) debottlenecking capex (FY26 onwards) driving volumes in high-margin products; (2) geographic expansion / new business wins. Organic growth 18-19% YoY (after price adjustment). Confident of sustaining at least 10% going forward.
Long-term revenue and margin outlook — Shashwat Singh, Bajaj
PartialRefrain from 5-year outlook due to dynamic external environment. Past 5 quarters show new level reached (last 2 quarters at ₹300+ Cr base revenue; prior 3 at lower level). Hope to sustain or grow from new level. Margins: 52-55% gross margin range; 25% ±1% EBITDA margin.
Ibuprofen profitability and timeline — Neeraj Shah, Individual Investor
PartialOn track for H1 solution. Hopeful to find solution by H1 timeline. Details in September.
Ibuprofen gross margin and EBITDA trends — Neeraj Shah, Individual Investor
AnsweredQ1 tactical play due to reduced solvent supply and higher demand. Not expecting long-term improvement; expect average of ₹10-15 Cr quarterly EBITDA loss to sustain.
Base vs ibuprofen business differentiation — Japreet Singh, Individual Investor
AnsweredCustomer relationships equivalent. Difference: ibuprofen commodity-driven, low value-chain position. Base business non-high-volume but complex manufacturing molecules with better margin/pricing profile.
FY27 business progress — Japreet Singh, Individual Investor
AnsweredThree pillars: (1) revenue growth: base business ₹250-245 Cr → ₹300+ Cr; (2) profitability: base business EBITDA ₹55 Cr → ₹70+ Cr (25.6% margin); (3) balance sheet: net debt reduced ₹135 Cr (22% reduction in 6-7 months).
Ibuprofen capital recovery and allocation — Achuth, Rockstar Equity Research
PartialNo strategic decision yet. Looking at options. H1 FY27 decision will provide clarity. Proceed allocation TBD.
Turnaround risks next 12-24 months — Abhay Amrutiya, Credence Wealth
AnsweredPrimary risk: West Asia crisis impact—managed so far but limited working capital means every rupee critical. Macro environment unpredictable. Second: raw material availability constraints (line shutdowns). Third: customer acceptance of price increases (not all willing; some resistance). Risks not in control but manageable.
10% growth guidance scope — Hiten, Sequent Investments
AnsweredMostly referring to base business. Q4 call guided 10% growth for base business for FY27. Not providing formal outlook; 10% is conservative given 24% delivered this quarter.
Guidance
Base business at least 10% YoY growth
HighConservative given 24% delivered Q1 FY27. No formal FY27 target, but reaffirmed in multiple Q&A responses. Assumes normalization post-West Asia crisis
Base business EBITDA margin 25% ±1%
HighReaffirmed from Q4 FY26 call. Q1 FY27 delivered 23.5% (below range due to cost headwinds); management expects reversion to 25% range once raw material costs normalize
Gross margin 50-55% base business
HighQ1 delivered 51.3% (adjusted 54.5% ex cost pass-through). Comfortable with range; aspiration to reach 55% end of range
FY27 capex ₹55-60 Cr; FY28-29 ₹40-50 Cr annually
HighFY27: ₹40 Cr debottlenecking (20-30% capacity gains, 2-3 quarter payback), ₹10-15 Cr maintenance. Similar split for FY28-29. No greenfield planned
Risks the call surfaced
Macro geopolitical
HighSolvent shortage from West Asia crisis causing intermittent line shutdowns, raw material availability constraints, and 30% cost inflation. Some customers accepting price increases, others resistant. Risk extends into H2 FY27 at least
Strategic capital allocation
High₹700 Cr capital deployed in ibuprofen business (debt + equity) earning -12% EBITDA margin with ₹10-15 Cr quarterly loss normalized. No clear exit plan articulated. Strategic review deferred to H1 FY27. Full capital recovery "slightly farfetched" per CFO. Risk of 20-30% write-down or divestment at discounted value
Revenue sustainability
MediumBase business 24% YoY growth delivered, but QoQ revenue flat (-1.5% consolidated, likely -2-3% base). Q1 seasonally weak in API. Post-West Asia normalization, if cost pass-through reverses and volumes don't accelerate, risk of growth falling below 10% guided level. Product mix (50-60 products, 15-16 drive 75%) adds concentration risk
Customer concentration
MediumSome customers resistant to accepting cost price increases amid West Asia crisis. If major customers shift to competitors or reduce orders, revenue could compress. Customer relationship strength not quantified; only assurance given is "historically strong quality record"
Leverage and debt refinancing
MediumNet debt still elevated at 1.9x annualized EBITDA (₹479 Cr). If base business growth slows below 10% or ibuprofen decision requires capex write-down, interest burden could strain margins. Refinancing risk if credit tightens
Management
Score 7/10. Transparent on headwinds (West Asia, ibuprofen) but evasive on ibuprofen exit timing. Provides detailed margin walk-throughs and cost decomposition. Declines to comment on individuals (CIO hire). Overall candid on constraints but hedges on forward guidance. Track record strong on base business (24% growth, 55% PAT growth), weak on ibuprofen (no progress on strategic review, losses normalized at -12% margin). Debt reduction impressive (₹135 Cr in Q1, 22% reduction). Met PAT guidance; missed revenue growth by 0.4%. Credibility B: delivers on profitability, defers on ibuprofen.
1 · Sep 2026 (Q2 FY27)
Ibuprofen strategic review conclusion expected; exit decision or turnaround plan
2 · Sep 2026
CRAMS demerger decision (retrofit Vizag or spin-off)
3 · FY27 onwards
₹55-60 Cr capex deployment on debottlenecking high-margin products (20-30% capacity gains)
Ibuprofen decision deferred again to H1 FY27 with no new clarity.